249 related articles for article (PubMed ID: 35444666)
41. Mycophenolate mofetil or tacrolimus compared with intravenous cyclophosphamide in the induction treatment for active lupus nephritis.
Li X; Ren H; Zhang Q; Zhang W; Wu X; Xu Y; Shen P; Chen N
Nephrol Dial Transplant; 2012 Apr; 27(4):1467-72. PubMed ID: 21917733
[TBL] [Abstract][Full Text] [Related]
42. Efficacy and safety of multi-target therapy using a combination of tacrolimus, mycophenolate mofetil and a steroid in patients with active lupus nephritis.
Ikeuchi H; Hiromura K; Takahashi S; Mishima K; Sakurai N; Sakairi T; Kaneko Y; Maeshima A; Kuroiwa T; Nojima Y
Mod Rheumatol; 2014 Jul; 24(4):618-25. PubMed ID: 24252014
[TBL] [Abstract][Full Text] [Related]
43. Comparative Efficacy and Safety of Biological Agents in the Treatment of Lupus Nephritis: A Network Meta-Analysis.
Lee YH; Song GG
Pharmacology; 2023; 108(1):17-26. PubMed ID: 36327917
[TBL] [Abstract][Full Text] [Related]
44. Multitarget therapy versus intravenous cyclophosphamide in the induction treatment of lupus nephritis: a metaanalysis of randomized controlled trials.
Deng J; Luo L; Zhu L; Xie H; xie H
Turk J Med Sci; 2018 Oct; 48(5):901-910. PubMed ID: 30384552
[TBL] [Abstract][Full Text] [Related]
45. Clinical efficacy and safety of rituximab in lupus nephritis.
Zhong Z; Li H; Zhong H; Zhou T
Drug Des Devel Ther; 2019; 13():845-856. PubMed ID: 30880917
[TBL] [Abstract][Full Text] [Related]
46. A pharmacoeconomic study comparing the use of mycophenolate mofetil or cyclophosphamide as induction therapy in lupus nephritis patients in Egypt.
Khattab NM; Abbassi M; A Raafat H; Farid S
Lupus; 2022 Apr; 31(4):505-516. PubMed ID: 35254887
[TBL] [Abstract][Full Text] [Related]
47. Mycophenolate mofetil for induction treatment of lupus nephritis: a systematic review and metaanalysis.
Touma Z; Gladman DD; Urowitz MB; Beyene J; Uleryk EM; Shah PS
J Rheumatol; 2011 Jan; 38(1):69-78. PubMed ID: 20952473
[TBL] [Abstract][Full Text] [Related]
48. Cost-effectiveness of cyclophosphamide and non-cyclophosphamide in the induction therapy of Malaysian lupus nephritis patients.
Rosli FZ; Shaharir SS; Abdul Gafor AH; Mohd R; Aizuddin AN; Osman S
Lupus; 2022 Aug; 31(9):1138-1146. PubMed ID: 35608373
[TBL] [Abstract][Full Text] [Related]
49. Efficacy and safety of mycophenolate mofetil and tacrolimus combination therapy in patients with lupus nephritis: a nationwide multicentre study.
Park DJ; Kang JH; Lee KE; Bae SC; Chung WT; Choe JY; Jung SY; Kim YS; Lee HS; Lee J; Lee YA; Park SH; Park YJ; Suh CH; Yoo DH; Lee SS
Clin Exp Rheumatol; 2019; 37(1):89-96. PubMed ID: 29998829
[TBL] [Abstract][Full Text] [Related]
50. Immunosuppressive Therapies for the Maintenance Treatment of Proliferative Lupus Nephritis: A Systematic Review and Network Metaanalysis.
Tian SY; Feldman BM; Beyene J; Brown PE; Uleryk EM; Silverman ED
J Rheumatol; 2015 Aug; 42(8):1392-400. PubMed ID: 26077406
[TBL] [Abstract][Full Text] [Related]
51. Outcome and predictors of renal survival in patients with lupus nephritis: Comparison between cyclophosphamide and mycophenolate mofetil.
Joo YB; Kang YM; Kim HA; Suh CH; Kim TJ; Park YW; Lee J; Lee JH; Yoo DH; Bae SC; Lee HS; Bang SY
Int J Rheum Dis; 2018 May; 21(5):1031-1039. PubMed ID: 29611341
[TBL] [Abstract][Full Text] [Related]
52. Effectiveness and tolerability of different therapies in preventive treatment of MOG-IgG-associated disorder: A network meta-analysis.
Wang X; Kong L; Zhao Z; Shi Z; Chen H; Lang Y; Lin X; Du Q; Zhou H
Front Immunol; 2022; 13():953993. PubMed ID: 35958613
[TBL] [Abstract][Full Text] [Related]
53. Con: Cyclophosphamide for the treatment of lupus nephritis.
Mok CC
Nephrol Dial Transplant; 2016 Jul; 31(7):1053-7. PubMed ID: 27190358
[TBL] [Abstract][Full Text] [Related]
54. Pilot study comparing the childhood arthritis and rheumatology research alliance consensus treatment plans for induction therapy of juvenile proliferative lupus nephritis.
Cooper JC; Rouster-Stevens K; Wright TB; Hsu JJ; Klein-Gitelman MS; Ardoin SP; Schanberg LE; Brunner HI; Eberhard BA; Wagner-Weiner L; Mehta J; Haines K; McCurdy DK; Phillips TA; Huang Z; von Scheven E;
Pediatr Rheumatol Online J; 2018 Oct; 16(1):65. PubMed ID: 30348175
[TBL] [Abstract][Full Text] [Related]
55. Effectiveness and safety of common therapeutic drugs for refractory lupus nephritis: A network meta-analysis.
Zhou J; Tao MJ; Jin LR; Sheng J; Li Z; Peng H; Xu L; Yuan H
Exp Ther Med; 2020 Jan; 19(1):665-671. PubMed ID: 31897105
[TBL] [Abstract][Full Text] [Related]
56. Evaluation of effect of empirical attack-preventive immunotherapies in neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis.
Ma J; Yu H; Wang H; Zhang X; Feng K
J Neuroimmunol; 2022 Feb; 363():577790. PubMed ID: 34959021
[TBL] [Abstract][Full Text] [Related]
57. Comparative efficacy of 13 immunosuppressive agents for idiopathic membranous nephropathy in adults with nephrotic syndrome: a systematic review and network meta-analysis.
Zheng Q; Yang H; Liu W; Sun W; Zhao Q; Zhang X; Jin H; Sun L
BMJ Open; 2019 Sep; 9(9):e030919. PubMed ID: 31511292
[TBL] [Abstract][Full Text] [Related]
58. Efficacy and safety of an anti-CD20 monoclonal antibody, rituximab, for lupus nephritis: A meta-analysis.
Teng S; Tian Y; Luo N; Zheng Q; Shao M; Li L
Int J Rheum Dis; 2022 Feb; 25(2):101-109. PubMed ID: 34811947
[TBL] [Abstract][Full Text] [Related]
59. Treatment for lupus nephritis: an overview of systematic reviews and meta-analyses.
Chen Y; Sun J; Zou K; Yang Y; Liu G
Rheumatol Int; 2017 Jul; 37(7):1089-1099. PubMed ID: 28493175
[TBL] [Abstract][Full Text] [Related]
60. Comparison of low-dose intravenous cyclophosphamide with oral mycophenolate mofetil in the treatment of lupus nephritis.
Rathi M; Goyal A; Jaryal A; Sharma A; Gupta PK; Ramachandran R; Kumar V; Kohli HS; Sakhuja V; Jha V; Gupta KL
Kidney Int; 2016 Jan; 89(1):235-42. PubMed ID: 26489028
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
